Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4609 External validation of Rachel score: A prognostic tool for lung neuroendocrine tumours

Introduction: Lung NETs are a heterogeneous group of tumours with variegated clinical presentation and course. The histological subtype (TC vs AC) and TNM stage are established prognostic factors. In a previous work by our group, we developed a prognostic model named Rachel score, with a satisfactory ability to predict OS and PFS in this population.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Marcozzi B, Lamberti G, Manai C, Mazzilli R,

Keywords: lung neuroendocrine tumour, prognostic tool, Rachel score, external cohort, validation,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4457 Primary mixed hepatocellular carcinoma-neuroendocrine carcinoma: A case report

Introduction: Mixed epithelial neoplasms (MiNENs) are characterised by the coexistence of neuroendocrine and non-neuroendocrine components within a single tumour, each discernible histologically and immunohistochemically, with a minimum tumour proportion of 30%. Primary hepatic MiNENs are exceedingly rare entities.

Conference:

Presenting Author: Tang Y

Authors: Wang Y, Wang R, Yi X, Guo M, Tang Y,

Keywords: pancreatic neuroendocrine tumour, functional, parathyroid hormone related peptide,

#4177 Performance of a prognostic OTP, CD44, Ki-67 biomarker panel on paired biopsies and resections of lung carcinoids

Introduction: Previously OTP, CD44 and ki-67 have been identified as prognostic biomarkers for lung carcinoid (LC).

Conference:

Presenting Author: van Weert T

Authors: van Weert T, Moonen L, Hillen L, von der Thüsen J, Lap L,

Keywords: OTP, CD44, Ki-67, lung carcinoid, relapse prediction,